Rafferty Asset Management LLC Sells 9,695 Shares of Zoetis Inc. $ZTS

Key Points

• Rafferty Asset Management LLC reduced its stake in Zoetis Inc. by 18.2%, selling 9,695 shares and holding a total of 43,478 shares worth $7,159,000.
• In its latest earnings report, Zoetis exceeded analysts' expectations with $1.76 earnings per share and revenue of $2.46 billion, marking a 4.2% increase year-over-year.
• Institutional investors control 92.80% of Zoetis's shares, with multiple firms adjusting their positions in recent months as stock ratings vary significantly among analysts.

Rafferty Asset Management LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 18.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,478 shares of the company's stock after selling 9,695 shares during the quarter. Rafferty Asset Management LLC's holdings in Zoetis were worth $7,159,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Lindbrook Capital LLC increased its position in shares of Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after acquiring an additional 65 shares in the last quarter. Quotient Wealth Partners LLC boosted its stake in Zoetis by 2.3% during the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after purchasing an additional 72 shares during the last quarter. Broadway Wealth Solutions Inc. increased its holdings in Zoetis by 4.4% during the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after purchasing an additional 73 shares in the last quarter. Menard Financial Group LLC raised its stake in shares of Zoetis by 3.8% in the first quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock worth $305,000 after purchasing an additional 75 shares during the last quarter. Finally, Moseley Investment Management Inc. raised its stake in shares of Zoetis by 1.4% in the first quarter. Moseley Investment Management Inc. now owns 5,719 shares of the company's stock worth $942,000 after purchasing an additional 77 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Up 0.4%

NYSE ZTS opened at $155.39 on Thursday. The stock has a market capitalization of $68.87 billion, a price-to-earnings ratio of 26.75, a PEG ratio of 2.48 and a beta of 0.88. The business's fifty day moving average is $153.53 and its 200-day moving average is $158.26. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Activity

In related news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.18% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ZTS shares. UBS Group decreased their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler boosted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.